Sunday, February 1, 2026 2/1/2026

Novel 3D DWI for Detection and Characterization of Prostate Cancer in Men with Pelvic Metal Implants

Award Number: R21CA277138
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/14/2023
PERIOD OF PERFORMANCE END DATE: 11/30/2026

Group Awards By:

View Award Description

Novel 3D DWI for Detection and Characterization of Prostate Cancer in Men with Pelvic Metal Implants - Project Summary Prostate cancer is the most common malignancy and the second leading cause of cancer-related mortality in men in the United States. The American Urological Association recommends the use of multiparametric magnetic resonance imaging (mpMRI) for diagnosis and disease management in all men at high risk for prostate cancer. mpMRI is also beneficial in men: 1) with an increasing prostate-specific antigen (PSA) following an initial negative prostate biopsy; 2) during longitudinal follow-up in active surveillance for biopsy- proven low-risk prostate cancer; and 3) for guidance of locally targeted therapies including cryotherapy, high intensity focused ultrasound (HIFU), MR-guided transurethral ultrasound ablation (TULSA), and emerging radioligand targeted treatments for intermediate to high-risk cancers. These recommendations are only realizable through accurate localization and characterization of individual prostate lesions on MRI, which is significantly challenging in men with pelvic metal implants. This is important since the incidence of prostate cancer increases substantially over 50 years of age and in parallel, the prevalence of hip replacement surgery also increases in that age group (estimated to reach ~4 million by 2030 in the US). Most of the metal implants in current clinical use are MR compatible, however, they distort the local magnetic field (B0) causing significant signal loss and image distortion. This is particularly problematic with echo-planar based diffusion-weighted imaging (EP-DWI), rendering these images non-diagnostic. This is a major limitation since DWI, according to the prostate imaging reporting and data system (PI-RADS) classification, is the pivotal sequence for lesion detection and characterization in the peripheral zone, where 70-75% of prostate cancers arise. To address this unmet clinical need, we propose to establish a 3D turbo spin echo (TSE) based DWI that is robust and can be widely implemented across all MR scanners. This is built upon our recently introduced novel acquisition and reconstruction strategy utilizing variable density Cartesian acquisition with spiral profile reordering (VD- CASPR). The volumetric acquisition of 3D VD-CASPR-DWI provides higher signal to noise ratio and the TSE readout improves the robustness to B0 inhomogeneities. This provides superior image quality and enables the visualization of the entire prostate gland without image distortions facilitating accurate detection and characterization of prostate lesions in men with pelvic metal implants. We will optimize the novel 3D VD- CASPR-DWI in phantoms and in-vivo prostate imaging of healthy volunteers. We will then validate this technique in 20 patients without and 20 patients with pelvic metal implants, evaluated for known or suspected prostate cancer. The successful outcome of this project will be an optimized mpMRI with our novel 3D VD- CASPR-DWI that provides pertinent clinical information for better management of prostate cancer patients and subsequently improve their quality of life and overall survival.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $203,727 )
2026	2026	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Detection and Diagnosis Research	000	3	12/11/2025	NON-COMPETING CONTINUATION	$203,727
														Subtotal = $203,727

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Detection and Diagnosis Research	000	1	2/25/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $191,675 )
2024	2024	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Detection and Diagnosis Research	002	2	8/15/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$183,475
2024	2024	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Detection and Diagnosis Research	000	1	12/14/2023	NEW	$191,675
2024	2024	THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Detection and Diagnosis Research	001	1	8/15/2024	NEW	-$183,475
														Subtotal = $191,675

Grand Total All Awards = $395,402

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Novel 3D DWI for Detection and Characterization of Prostate Cancer in Men with Pelvic Metal Implants

Award Number: R21CA277138

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/14/2023

PERIOD OF PERFORMANCE END DATE: 11/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer